

## 2024 AAPS PharmSci 360 - Poster Abstract Tracks (Subtracks) | Primary Topics | Keywords = (Review Groups)

There are five robust tracks covering all aspects of the pharmaceutical sciences. Three tracks are divided into two subtracks with Biomolecular and Chemical focuses. The Tracks Discovery and Basic Research and Preclinical, Clinical, and Translational Sciences, are not split into subtracks.

**IMPORTANT NOTE:** In the submission site the structure below, Track (Subtrack), Primary Topic, and Keywords, are referred to as Review Groups. Screeners, please select all Review Groups that apply to your expertise.

### Review Group Selection Process

**1. Select the Track-Subtrack that best fits your research. (see below)**

- \* Discovery and Basic Research
- \* Preclinical, Clinical, and Translational Sciences
- \* Bioanalytics
- \* Manufacturing and Analytical Characterization
- \* Formulation and Delivery

**2. Select the Subtrack (Biomolecular or Chemical).** Doesn't apply to the Discovery and Basic Research and Preclinical, Clinical, and Translational Sciences tracks.

**3. Select the Primary Topic that best fits your research.**

**4. From your Primary Topic, select the best Keywords for your research. If no listed Keywords fits your research, select 'Other'. (Note: In some instances there are no Keywords.)**

TRACK (SUBTRACK)	PRIMARY TOPIC	KEYWORDS
Discovery and Basic Research	Bioanalytical	New Applications of Existing Technology
		New Approaches
		New Technology
Discovery and Basic Research	Biology	Biomarkers
		Cell Therapy CAR-T, STEM Cell, Other
		Cellular and Molecular Pathways
		Gene Therapy
		Immunogenicity
		In Silico
		In Vitro
		In Vivo
		Metabolizing Enzymes
		Omics
		Protein Binding
		Protein/Gene Engineering and Expression
		Receptor/Target Interactions
		Target Identification
Transporter		
Discovery and Basic Research	Medicinal Chemistry	Combinatorial Chemistry
		Fragment Based Design
		In Silico Based Design
		Natural Products
		Novel Drug Modality
		Peptides and other Large Molecules
		Rational Drug Design
		Small Molecules
		Structure Activity Relationship
		Synthetic Chemistry
		Drug Delivery Novel Systems

TRACK (SUBTRACK)	PRIMARY TOPIC	KEYWORDS
Discovery and Basic Research	Pharmaceutics	<ul style="list-style-type: none"> <li>Drug Delivery Ocular</li> <li>Drug Delivery Transdermal</li> <li>Drug Transport and Transporters</li> <li>Modeling and Simulation: New Approaches</li> <li>Molecular Biopharmaceutics</li> <li>Novel Drug Modality</li> <li>Pharmaceutical Polymers</li> <li>Pharmacokinetics</li> </ul>
Discovery and Basic Research	Pharmacology	<ul style="list-style-type: none"> <li>Behavioral Pharmacology</li> <li>Bioanalytical</li> <li>Biomarkers</li> <li>Cell Death and Differentiation</li> <li>DNA Damage and Repair</li> <li>Drug Abuse</li> <li>Drug-Drug Interactions</li> <li>Epigenetics and Epigenetic Therapy</li> <li>Experimental Therapeutics</li> <li>Gene Therapy</li> <li>Immunotherapy and Immunopharmacology</li> <li>Natural Products</li> <li>Neuropharmacology</li> <li>Omics (genomics, metabolomics, epigenomics, proteomics)</li> <li>Oncology (hematologic malignancies)</li> <li>Oncology (solid tumors)</li> <li>Orphan Drugs and Rare Diseases</li> <li>Pharmacokinetics</li> <li>Quantitative Pharmacology</li> <li>Signal Transduction</li> <li>Systems Pharmacology</li> <li>Toxicology</li> <li>Vaccines</li> </ul>
Preclinical, Clinical, and Translational Sciences	ADME	<ul style="list-style-type: none"> <li>Biotransformation (In Vitro and In Vivo)</li> <li>High Throughput Assays</li> <li>Metabolite Identification and Characterization</li> <li>Metabolizing Enzymes Biotransformation (In Vitro and In Vivo)</li> <li>Novel Drug Modality/Novel Drug Delivery</li> <li>Optimization of Protein Design</li> <li>Payload-Linker Identification/Optimization</li> <li>Permeability, Distribution, and Site of Action</li> <li>Pharmacokinetics</li> <li>Screening Tools for Candidate Optimization</li> <li>Transporters Biotransformation (In Vitro and In Vivo)</li> <li>Other</li> </ul>
Preclinical, Clinical, and Translational Sciences	Biomarkers	<ul style="list-style-type: none"> <li>Clinical Qualification</li> <li>Disease Heterogeneity Assessments</li> <li>Endpoints (Surrogate , Primary, Secondary, Exploratory)</li> <li>High Content Data Analysis</li> <li>Novel Biomarkers</li> <li>Observational/Epidemiology Studies</li> <li>Patient Selection</li> <li>Bayesian Methods</li> </ul>

TRACK (SUBTRACK)	PRIMARY TOPIC	KEYWORDS
Preclinical, Clinical, and Translational Sciences	Biostatistical Methodologies	<ul style="list-style-type: none"> <li>Clinical Study Design</li> <li>Regulatory Recommendations</li> <li>Statistical Analysis Models</li> <li>Statistical Reporting</li> <li>Tools/Software</li> <li>Other</li> </ul>
Preclinical, Clinical, and Translational Sciences	Clinical Trials	<ul style="list-style-type: none"> <li>Designs and Methodology (Including QdB and RBM)</li> <li>Dosing Strategies</li> <li>Drug Interaction Studies</li> <li>Ethics in Clinical Trials</li> <li>Ex-US and Multi-national Studies</li> <li>Monitoring</li> <li>Patient Stratification</li> <li>Real World Evidence</li> <li>Regulatory Guidance</li> <li>Special Population Studies</li> <li>Other</li> </ul>
Preclinical, Clinical, and Translational Sciences	Immunogenicity	<ul style="list-style-type: none"> <li>Clinical Relevance</li> <li>Factor in Species Selection</li> <li>Immunogenicity Risk Assessment</li> <li>Impact on Exposure</li> <li>Impact on Safety Assessment</li> <li>Integrated Summary of Immunogenicity</li> <li>Post-Marketing Surveillance and REMS</li> </ul>
Preclinical, Clinical, and Translational Sciences	Modalities	<ul style="list-style-type: none"> <li>ADCs</li> <li>Alternative Scaffold</li> <li>Bispecifics, Trispecifics and Higher Order Complexities</li> <li>CAR-T and Other Modified Cell Lines</li> <li>Cell-Based Therapy</li> <li>Encapsulated Drugs (Lipid, Nanoparticle, and Viral Vectors)</li> <li>Multispecific Antibodies</li> <li>Nanoparticle-Based</li> <li>Oligos, RNAs, and Locked Nucleic Acids</li> <li>PROTACs and Similar Molecular Glues</li> <li>Small Molecules</li> <li>Vaccines</li> <li>Other</li> </ul>
Preclinical, Clinical, and Translational Sciences	Modeling and Simulation	<ul style="list-style-type: none"> <li>Absorption Modeling</li> <li>Advanced Modeling Approaches</li> <li>Big Data and Artificial Intelligence</li> <li>Comparator Modeling</li> <li>Dose Project/Selection and Justification</li> <li>Drug interactions</li> <li>Imaging Based Approach</li> <li>In Vivo-In Vitro Correlation (IVIVC) Modeling</li> <li>Maternal/Fetal PK Model</li> <li>Other Special Populations</li> <li>Pediatric Model</li> <li>PK/PD Modeling</li> <li>Population PK Modeling</li> <li>Quantitative Systems Pharmacology (QSP)</li> </ul>

TRACK (SUBTRACK)	PRIMARY TOPIC	KEYWORDS
		Resources, Tools and Software Standardization and Regulatory Advancement Translational Modeling Other
Preclinical, Clinical, and Translational Sciences	OMICS	Genomics Metabolomics Proteomics Other
Preclinical, Clinical, and Translational Sciences	Regulatory Guidance/Submissions	Clinical Study Reports (CSRs) Clinical Trial Protocols Data Standards and Management (Including CDISC) Harmonization and Guidance Documents Health Authority Interactions/Meetings Labeling Regulatory Filings and Submissions Safety Other
Preclinical, Clinical, and Translational Sciences	Safety	Cellular and Molecular Toxicology De-risking Strategies Genetic Toxicity Immuno-toxicity IND Enabling Studies Mechanistic Toxicity Screening Toxicity Studies Other
Preclinical, Clinical, and Translational Sciences	Translation	Drug-Drug Interaction (DDI) Formulation Selection Human PK and Dose Projections Patient Selection PK/PD Safety Other
Preclinical, Clinical, and Translational Sciences	Type of Human Studies	Adaptive and Accelerated Designs Bioequivalence Biosimilars Diseased Patient Population Studies Drug-Drug Interaction (DDI) First-Time-in-Human (FTIH) Food Effect Geriatric Organ Impairment Other Special Populations Pediatric Pregnant Women Radio-Labeled Mass Balance, Microdose and ADME Registrational Studies and Strategies Relative and Absolute Bioavailability Thorough QT/QTc (TQT) Other
Bioanalytics - Biomolecular	Analyte Stability	Ex Vivo In Vitro

TRACK (SUBTRACK)	PRIMARY TOPIC	KEYWORDS
		Solution
Bioanalytics - Biomolecular	Bioanalytical Innovations and Applications	n/a
Bioanalytics - Biomolecular	Bioanalytical Risk Assessment and Strategy	n/a
Bioanalytics - Biomolecular	Biomarker Quantification	Biomarker/Pharmacodynamic Measurement Clinical Qualification Diagnostic Development (including companion diagnostics) Disease Heterogeneity Assessments Exosome Flow Cytometry Methods High Content Data Analysis Hybrid Methods (e.g. IP/LCMS) Imaging Methods Ligand Binding Assay (LBA) Methods Mass Spectrometry (LC-MS) Methods New Matrices New Modalities OMICs PCR Methods Preanalytical Variables Single-Cell-Based Biomarkers Target Engagement/Receptor Occupancy Vaccines
Bioanalytics - Biomolecular	Drug Quantification	Endogenous Homologs Quantification Flow Cytometry Methods Hybrid Methods (e.g. IP/LCMS) Imaging Methods Ligand Binding Assay (LBA) Methods Mass Spectrometry (LC-MS) Methods PCR Methods Other Methods/Techniques Therapeutic Drug Monitoring Post-marketing Commitment Surrogate Analyte
Bioanalytics - Biomolecular	Immunogenicity	Binding Antibody Methods Cell-Based Methodologies Neutralizing Antibody Methods Immunogenicity Risk Assessments Immunogenicity Prediction
Bioanalytics - Biomolecular	In Vivo and Ex Vivo Biotransformation	ADC Metabolism Evaluation of In Vivo Biotransformation Impact of Biotransformation on Immunogenicity Impact of Biotransformation on PK Molecule Variants Quantification Ex Vivo
Bioanalytics - Biomolecular	Life Cycle Management of Bioanalytical Methods	Collaboration with other Partners (Co-development) Data Management General Life Cycle Management Methods Transfer and CRO Management
		ADCs Alternative Scaffold CAR-T Cell-Based Therapy

TRACK (SUBTRACK)	PRIMARY TOPIC	KEYWORDS
Bioanalytics - Biomolecular	Novel Modalities	Encapsulated Drugs (Lipid, Nanoparticle, etc.) Multi-specific Antibodies Nanoparticle Based Modalities Oligos, RNAs, and Locked Nucleic Acids Viral Vectors Other
Bioanalytics - Biomolecular	Reagents and Reference Standards	Characterization and Quality Control Life Cycle Management Stability
Bioanalytics - Biomolecular	Regulations (BMV/GLP/GCP/CLIA)	Biomarkers Drug (and Metabolites) GCP/GLP Compliance for Bioanalytical Labs General Topics ICH and Harmonization Immunogenicity and Risk Assessment Samples and Reagent Stability
Bioanalytics - Biomolecular	Samples and Laboratory Management	Bioanalytical Documentation and Reports Biorepositories Informed Consent Laboratory Information Management System (LIMS) Patient-Centric Sampling (microsampling and dried blood spots) Post-Collection Sample Condition and Record Management
Bioanalytics - Biomolecular	Vaccines	Binding Antibody Methods Cell-Based Methodologies Correlates of Protection Neutralizing Antibody Methods
Bioanalytics - Chemical	Analyte Stability	Ex Vivo In Vitro Solution
Bioanalytics - Chemical	Bioanalytical Innovations and Applications	n/a
Bioanalytics - Chemical	Bioanalytical Risk Assessment and Strategy	n/a
Bioanalytics - Chemical	Biomarker Quantification	Biomarker/Pharmacodynamic Measurement Clinical Qualification Diagnostic Development (including companion diagnostics) Disease Heterogeneity Assessments Exosome Flow Cytometry Methods High Content Data Analysis Hybrid Methods (e.g. IP/LCMS) Imaging Methods Ligand Binding Assay (LBA) Methods Mass Spectrometry (LC-MS) Methods New Matrices New Modalities OMICs PCR Methods Preanalytical Variables Single-Cell-Based Biomarkers Target Engagement/Receptor Occupancy Endogenous Homologs Quantification Flow Cytometry Methods

TRACK (SUBTRACK)	PRIMARY TOPIC	KEYWORDS
Bioanalytics - Chemical	Drug Quantification	Hybrid Methods (e.g. IP/LCMS) Imaging Methods Ligand Binding Assay (LBA) Methods Mass Spectrometry (LC-MS) Methods PCR Methods Other Methods/Techniques Therapeutic Drug Monitoring Post-marketing Commitment Surrogate Analyte
Bioanalytics - Chemical	Immunogenicity	Binding Antibody Methods Cell-Based Methodologies Immunogenicity Prediction Immunogenicity Risk Assessments Neutralizing Antibody Methods
Bioanalytics - Chemical	In Vivo and Ex Vivo Biotransformation	ADC Metabolism CYP450 Assessment Evaluation of In Vivo Biotransformation Impact of Biotransformation on Immunogenicity Impact of Biotransformation on PK Metabolite Quantification
Bioanalytics - Chemical	Life Cycle Management of Bioanalytical Methods	Collaboration with other Partners (Co-development) Data Management General Life Cycle Management Methods Transfer and CRO Management
Bioanalytics - Chemical	Novel Modalities	ADCs Alternative Scaffold CAR-T Cell-Based Therapy Encapsulated Drugs (Lipid, Nanoparticle, etc.) Multi-specific Antibodies Nanoparticle Based Modalities Oligos, RNAs, and Locked Nucleic Acids Viral Vectors Other
Bioanalytics - Chemical	Reagents and Reference Standards	Characterization and Quality Control Life Cycle Management Stability
Bioanalytics - Chemical	Regulations (BMV/GLP/GCP/CLIA)	Biomarkers Drug (and Metabolites) GCP/GLP Compliance for Bioanalytical Labs General Topics ICH and Harmonization Immunogenicity and Risk Assessment Samples and Reagent Stability
Bioanalytics - Chemical	Samples and Laboratory Management	Bioanalytical Documentation and Reports Biorepositories Informed Consent Laboratory Information Management System (LIMS) Patient-Centric Sampling (microsampling and dried blood spots) Post-Collection Sample Condition and Record Management
		Combination Products

TRACK (SUBTRACK)	PRIMARY TOPIC	KEYWORDS
Manufacturing and Analytical Characterization - Biomolecular	Analytical	Excipients Immunogenicity Impurities Modality Specific Methods - Cell Therapy Modality Specific Methods - Free Oligonucleotide Modality Specific Methods - Gene Therapy Modality Specific Methods - Protein Modality Specific Methods - Vaccine/Tolerance Induction Modality Specific Methods - Other New Technology Potency/Bioassay (Sub)visible Particles Other
Manufacturing and Analytical Characterization - Biomolecular	Automation	Computer Validation Other
Manufacturing and Analytical Characterization - Biomolecular	Biosimilar Manufacturing	Biosimilarity Assessment Patent Protection Other
Manufacturing and Analytical Characterization - Biomolecular	Drug Product Manufacturing and Development	Aseptic Technologies - Mixing, Sterilization, and Filling Cell Therapies Freezing and Thawing Immunogenicity and Critical Quality Attributes Lyophilization and Drying Technologies Manufacturing and Assembly of Drug/Device Combinations Manufacturing of Drug Delivery Systems Primary Packaging - Container Closure Integrity Primary Packaging - Syringes Primary Packaging - Vials Primary Packaging - Other Process Characterization and Optimization Protein Aggregation and Degradants Secondary Packaging Storage Considerations Vaccines Viral and Non-viral Vectors and Gene Therapy Visible and Subvisible Particles Visual Inspection Other
Manufacturing and Analytical Characterization - Biomolecular	Drug Substance Manufacturing and Development	API Packaging and Storage Cell Line Development Cell Therapies Clonality Assessments Expression Systems - Cellular and Cell-Free Genetic and Cell Line Engineering Mammalian Cell Culture Media Development Microbial/Yeast Fermentation Process Optimization and Intensification Protein Aggregation during Processing and Immunogenicity Purification and Virus Removal Vaccines



TRACK (SUBTRACK)	PRIMARY TOPIC	KEYWORDS
		Virus Safety/Removal Viral and Non-viral Vectors and Gene Therapy Other
Manufacturing and Analytical Characterization - Biomolecular	General Aspects and Strategies	Change Control CMO Management Drug Master Files Drug Substance and Drug Product Shipment Electronic Records Handling Control Substances (DEA) Inspections and GMP Lean Manufacturing/Six Sigma/Operational Excellence Life Cycle Management Manufacturing Economics Materials Management and Warehousing Regulatory Strategy Supply Chain Other
Manufacturing and Analytical Characterization - Biomolecular	Health, Safety, and Environment	Containment and Isolators High-Potent Drug Manufacturing OEL and PDE Other
Manufacturing and Analytical Characterization - Biomolecular	Innovative/Novel Processing Technologies and Concepts	For Use in Drug Product Manufacture For Use in Drug Substance Manufacture Other
Manufacturing and Analytical Characterization - Biomolecular	Integrated and Continuous Processing and Manufacturing	For Use in Drug Product Manufacture For Use in Drug Substance Manufacture Other
Manufacturing and Analytical Characterization - Biomolecular	Manufacture of Clinical Supplies	Blinding of Comparator Drugs Phase Appropriate GMP Speed to Patient Other
Manufacturing and Analytical Characterization - Biomolecular	Plant Engineering and Maintenance	Facility Design Legacy Facility Innovation/Renovation Media Media Fills Media/Buffer Preparation and Fluid Management Modeling and Scheduling Multiproduct Batch Plants Modular Manufacturing Plant Incident Investigations Other
Manufacturing and Analytical Characterization - Biomolecular	Process Design and Controls	Cleaning Validation Control of Impurity Formation In-Process Controls Process Analytical Technology and Parametric/Real-Time Release Process Modeling and Simulations Process Validation/Continuous Process Validation QbD and Assessment of Process Parameters Scale-Up/Process Transfers Statistical Process Controls and Six Sigma Use of Prior Knowledge and Risk-Based Approaches Other

TRACK (SUBTRACK)	PRIMARY TOPIC	KEYWORDS
Manufacturing and Analytical Characterization - Biomolecular	Single-Use and Disposable Systems	<ul style="list-style-type: none"> <li>For Use in Drug Product Manufacture</li> <li>For Use in Drug Substance Manufacture</li> <li>Leachables and Extractables</li> <li>Other</li> </ul>
Manufacturing and Analytical Characterization - Chemical	Analytical	<ul style="list-style-type: none"> <li>Continuous/Real-Time Release</li> <li>Drug Release Measurement - Biorelevant Dissolution</li> <li>Drug Release Measurement - Cascade Impaction</li> <li>Drug Release Measurement - Dissolution</li> <li>Drug Release Measurement - Forms</li> <li>Drug Release Measurement - Other</li> <li>Excipients</li> <li>Impurities and Degradation - Forced Degradation</li> <li>Impurities and Degradation - Impurity Quantitation</li> <li>Impurities and Degradation - In Silico Prediction of Stability</li> <li>Impurities and Degradation - Other</li> <li>Method Development Strategies</li> <li>Model Maintenance</li> <li>New Analytical Technologies</li> <li>Physical Characterization Techniques</li> <li>Process Analytical Technology and Continuous Release Testing</li> <li>Real Time Release testing</li> <li>Other</li> </ul>
Manufacturing and Analytical Characterization - Chemical	Automation	<ul style="list-style-type: none"> <li>Computer Validation</li> <li>Other</li> </ul>
Manufacturing and Analytical Characterization - Chemical	Drug Product Manufacturing and Development	<ul style="list-style-type: none"> <li>Aseptic Technologies and Sterilization - Filling</li> <li>Aseptic Technologies and Sterilization - Filtration</li> <li>Aseptic Technologies and Sterilization - Mixing</li> <li>Aseptic Technologies and Sterilization - Other</li> <li>Bulk Packaging</li> <li>Freezing and Thawing</li> <li>Immunogenicity and Critical Quality Attributes</li> <li>Liquids Manufacture - Oral and Topical Liquids</li> <li>Liquids Manufacture - Other</li> <li>Lyophilization and Drying Technologies</li> <li>Manufacturing and Assembly of Drug/Device Combinations</li> <li>Manufacturing of Aerosols and DPI</li> <li>Manufacturing of Drug Delivery Systems</li> <li>Primary Packaging - Blisters</li> <li>Primary Packaging - Bottles</li> <li>Primary Packaging - Container Closure Integrity</li> <li>Process Optimization</li> <li>Secondary Packaging</li> <li>Semi-solids Manufacture - Cremes</li> <li>Semi-solids Manufacture - Liposomes, Solid Lipid Nanoparticles</li> <li>Semi-solids Manufacture - Other</li> <li>Shipping Studies</li> <li>Solids Manufacture - Capsules</li> <li>Solids Manufacture - Drug Product Intermediates</li> <li>Solids Manufacture - Mini-tablets</li> <li>Solids Manufacture - Powders</li> <li>Solids Manufacture - Tablets and Granules</li> </ul>

TRACK (SUBTRACK)	PRIMARY TOPIC	KEYWORDS
		Solids Manufacture - Other Storage Considerations Visual Inspection Other
Manufacturing and Analytical Characterization - Chemical	Drug Substance Manufacturing and Development	API Kilo Lab API Packaging and Storage Control of Impurity Formation Crystal Structure/Polymorph Screening Crystallization Development Filtration Genotoxic Impurities Immunogenicity and Critical Quality Attributes Milling and Micronization Technologies Particle Size Control Process Chromatography Process Optimization Purification Other
Manufacturing and Analytical Characterization - Chemical	General Aspects and Strategies	Change Control CMO Management Drug Master Files Drug Substance and Drug Product Shipment Electronic Records Handling Control Substances (DEA) Inspections and GMP Lean Manufacturing/Six Sigma/Operational Excellence Life Cycle Management Manufacturing Economics Materials Management and Warehousing Regulatory Strategy Supply Chain Other
Manufacturing and Analytical Characterization - Chemical	Generic Manufacturing	Patent Protection Pharmaceutical Equivalence Assessment Other
Manufacturing and Analytical Characterization - Chemical	Health, Safety, and Environment	Containment and Isolators Explosion Protection Green Chemistry High-Potent Drug Manufacturing OEL and PDE Solvent Recovery Other
Manufacturing and Analytical Characterization - Chemical	Innovative/Novel Processing Technologies and Concepts	For Use in Drug Product Manufacture For Use in Drug Substance Manufacture Other
Manufacturing and Analytical Characterization - Chemical	Integrated and Continuous Processing and Manufacturing	For Use in Drug Product Manufacture For Use in Drug Substance Manufacture Other
Manufacturing and Analytical Characterization - Chemical	Manufacture of Clinical Supplies	Blinding of Comparator Drugs Phase Appropriate GMP Other

TRACK (SUBTRACK)	PRIMARY TOPIC	KEYWORDS
Manufacturing and Analytical Characterization - Chemical	Plant Engineering, Equipment and Maintenance	Clean Media Facility Design Media Media Fills Modeling and Scheduling Multiproduct Batch Plants Modular Manufacturing Plant Incident Investigations Other
Manufacturing and Analytical Characterization - Chemical	Process Design and Controls	Cleaning Validation Control of Impurity Formation In-Process Controls Process Analytical Technology and Parametric/Real-Time Release Process Modeling and Simulations Process Validation QbD and Assessment of Process Parameters Robustness/CPV Continuous Process Verification Scale-Up/Process Transfers Statistical Process Controls and Six Sigma Use of Prior Knowledge and Risk-Based Approaches Other
Manufacturing and Analytical Characterization - Chemical	Single-Use and Disposable Systems	For Use in Drug Product Manufacture For Use in Drug Substance Manufacture Leachables and Extractables Other
Formulation and Delivery - Biomolecular	Administration	DP Handling In-Use Compatibility Nasal/Pulmonary Ocular Otic Potent Modalities Sterility and Microbiology Strategies Transdermal Other
Formulation and Delivery - Biomolecular	Drug Delivery	Extended Release (Non-implant) Implants On Body Delivery Systems (OBDS) Other Routes of Administration - Ocular Other Routes of Administration - Otic Other Routes of Administration - Transdermal and Topical Other Routes of Administration - Other Other
Formulation and Delivery - Biomolecular	Drug Delivery, Devices, and Drug Device	Design Control Hardware Human Factor Engineering New Delivery Technologies Patient-Centric Development Software
		Cell Therapy Free Oligonucleotide Gene Therapy

TRACK (SUBTRACK)	PRIMARY TOPIC	KEYWORDS
Formulation and Delivery - Biomolecular	Formulation	Protein - Developability Assessment Protein - Excipients Protein - High-Throughput Screening Protein - Lyo Protein - Syringes Protein - Topics Protein - Other Vaccine/Tolerance Induction Other
Formulation and Delivery - Biomolecular	Primary Packaging	Compatibility Container Closure Integrity Extractables/Leachables New Materials
Formulation and Delivery - Biomolecular	Regulatory Considerations	Accelerated Approval Pathways Bioequivalence Biosimilars Innovative Technologies Inspections and GMPs Large Market Developments New Regulations and Guidances Risk Assessment Implementation Smaller Market Developments Stability Requirements (Sub)visible Particles
Formulation and Delivery - Chemical	Biopharmaceutics	BCS, DCS Bioequivalence (also Regulatory) Comparability Assessments IVIVC Predictive Modeling Other
Formulation and Delivery - Chemical	Drug Delivery	Extended Release (Non-implant) Implants Other Routes of Administration - Ocular Other Routes of Administration - Otic Other Routes of Administration - Transdermal and Topical Other Routes of Administration - Other Nanoparticles Other
Formulation and Delivery - Chemical	Drug Delivery, Devices, and Drug Device	Design Control Hardware Human Factor Engineering New Delivery Technologies Patient-Centric Development Software
Formulation and Delivery - Chemical	Formulation	Advanced Dissolution Testing Amorphous and Co-crystal Systems Bioavailability Enhancement Drug Substance Properties Excipients Fixed Dose Combinations Inhalation and Nasal

TRACK (SUBTRACK)	PRIMARY TOPIC	KEYWORDS
		Oral - Immediate Release Oral - Modified Release Parenterals Predictive Modeling Preformulation Special Populations
Formulation and Delivery - Chemical	Primary Packaging	Compatibility Container Closure Integrity Extractables/Leachables New Materials
Formulation and Delivery - Chemical	Regulatory Considerations	Accelerated Approval Pathways Bioequivalence Biosimilars Innovative Technologies Inspections and GMPs Large Market Developments New Regulations and Guidances Patient Focused Drug Development Guidelines Risk Assessment Implementation Smaller Market Developments Stability Requirements (Sub)visible Particles